Fordham 33 (Report 4): Life Sciences and Healthcare Innovation

Key Takeaways

• European protocols disclose methods, not results, limiting anticipatory rejections
• Subsequent‑innovation patents hinge on competitive edge and IRA pricing timelines
• UK plausibility test G2/21 still misaligned with broader Europe
• Japan’s revised linkage system adds expert committee, may boost generics
• UPC centralization can jeopardize entire life‑science patent portfolios

Pulse Analysis

The transatlantic divide in patent practice is widening as Europe continues to treat clinical‑trial protocols as method disclosures, leaving the therapeutic outcome out of the claim scope. This approach, coupled with product‑for‑use claims, means that a protocol alone rarely anticipates a later patent, forcing applicants to balance early filing against the need for human data. In contrast, U.S. courts focus on functional features, creating a more flexible but unpredictable environment for life‑science innovators.

Pharmaceutical firms are now recalibrating their IP roadmaps around the Inflation Reduction Act, which forces price drops after seven years for small molecules and eleven for biologics. The resulting pressure pushes companies to prioritize subsequent‑innovation patents—covering new formulations, dosing regimens, or indications—while weighing the diminishing returns of extensive patent thickets. Meanwhile, the UK’s G2/21 plausibility test remains out of step with continental Europe, and the CJEU’s narrow rulings on supplementary protection certificates perpetuate litigation cycles, as seen in the Merck v Clonmel decision.

Japan’s recently overhauled linkage system introduces a three‑member expert committee to assess patent‑infringement questions, aiming to streamline generic approvals while preserving originator rights. Though confidentiality persists, the new framework is expected to increase generic market entry, potentially sparking more patent disputes. Across the board, the UPC’s centralized adjudication poses a double‑edged sword: it can streamline enforcement but also expose an entire portfolio to a single adverse ruling. Practitioners must therefore craft meticulous, evidence‑rich briefs and stay attuned to jurisdiction‑specific nuances to safeguard their clients’ innovations.